XanthoPharm Welcomes Drs Andrea Natale and Sanghamitra Mohanty
to its Scientific Advisory Board (SAB)
Weymouth, MA. March 18, 2021
XanthoPharm, a therapeutics company dedicated to developing novel therapeutics for the treatment of arrhythmias welcomes Drs. Andrea Mohanty and Sanghamitra Mohanty to its SAB. Drs. Natale and Mohanty will be significant resource for XanthoPharm to provide scientific review and strategic advice about the company’s development strategy.
“We are honored to officially welcome Drs. Natale and Mohanty as members of our SAB,” said Bob Jenkins, CEO of XanthoPharm. “Dr. Natale´s pioneering research and vast clinical experience in the area of arrythmias will help us develop our research strategy in the future and Dr. Mohanty´s extensive research experience in the therapeutics of arrhythmia and clinical studies in Atrial Fibrillation will also be invaluable to us.”
The SAB will be involved in strategic discussions related to our research, both clinical and pre-clinical, as well as our developmental strategy and pipeline.
About Andrea Natale MD, FACC
Dr. Natale is the Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and the National Medical Director of Cardiac Electrophysiology for HCA Healthcare. Dr. Natale is board certified in Cardiology and Clinical Cardiac Electrophysiology.
He is a dedicated researcher who has pioneered several innovative advances in the treatment of atrial fibrillation, including some of the current catheter-based cures for atrial fibrillation, a new circumferential ultrasound vein-ablation system to correct atrial fibrillation and was the nation’s first electrophysiologist to perform percutaneous epicardial radiofrequency ablation. Dr. Natale has held faculty positions at Duke University, Case Western Reserve University, Stanford University and the Dell Medical School at the University of Texas at Austin.
About Sanghamitra Mohanty. MD, MS, FHRS
Dr. Mohanty serves as the Director of Research at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. Currently, Dr. Mohanty is involved in leading several major research projects and clinical trials in patients with atrial fibrillation.
Dr. Mohanty performed post-graduate studies at the University of North Texas Health Science Center in Fort Worth, Texas and worked as a researcher and faculty at The University of Texas at Austin. At UT, she was directly involved in the development of novel tests to detect cardiac biomarkers for the diagnosis and monitoring of treatment in heart disease. Dr. Mohanty is an affiliate faculty member at Dell Medical School, Austin, TX.
About XanthoPharm
XanthoPharm is a therapeutics company dedicated to the development of Xanthohumol for the treatment of Arrhythmias in general and Atrial Fibrillation in particular.
Atrial Fibrillation is the most common of all arrhythmias and its pharmaceutical management problematic. Our goal is to bring therapeutic to Afib patients that is both efficacious and safe.